Results 111 to 120 of about 79,311 (270)

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs [PDF]

, 2013
Oncolytic viruses are emerging as a potential new way of treating cancers. They are selectively replication-competent viruses that propagate only in actively dividing tumor cells but not in normal cells and, as a result, destroy the tumor cells by ...
Braidwood, L., Conner, J., Graham, A., Graham, S.V.   +3 more
core   +1 more source

Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences [PDF]

, 2015
Herbal medicines are currently in high demand, and their popularity is steadily increasing. Because of their perceived effectiveness, fewer side effects and relatively low cost, they are being used for the management of numerous medical conditions ...
Horie, Toshiharu, Oga, Enoche Florence, Sekine, Shuichi, Shitara, Yoshihisa   +3 more
core   +1 more source

Oxaliplatin‐induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose–response relationship and impact on quality of life

International Journal of Cancer, EarlyView.
What's New? Oxaliplatin serves a key role in the treatment of rectal cancer, though it is a significant cause of chemotherapy‐induced peripheral neuropathy. As total neoadjuvant therapy, in which all therapy is given before surgery, has become more common, understanding neuropathy has grown increasingly important. This study examined neuropathy and its
Georg W. Wurschi, Andreas Hinz, Melanie Schneider, Jan‐Niklas Becker, Bernd Frerker, Samuel M. Vorbach, Felix Ehret, Markus Diefenhardt, Fabian Schunn, Maria‐Elena von Gruben, Marcel Büttner, Elgin Hoffmann, Alexander Rühle, Josephine Beier, Simone Ferdinandus, Maike Trommer, Ezgi Ceren Sahin, Julian Hlouschek, Kynann Aninditha, Daphne Schepers von Ohlen, Justus Kaufmann, Alina Depardon, Hai Minh Ha, Christopher Kessler, Adrianna Cieslak, Simon Trommer, Alexander Fabian, Florian Rißner, Maximilian Römer, Klaus Pietschmann   +29 more
wiley   +1 more source

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer

Cancer Treatment and Research Communications
Purpose: There is evidence that adding cetuximab can overcome resistance to irinotecan, but a similar analysis with Panitumumab isn't readily available. This study evaluated the activity of each anti-EGFR plus irinotecan as a salvage third-line treatment
Maria Ignez Freitas Melro Braghiroli, Daniel Santos Rocha Sobral Filho, Juliana Goes Martins Fagundes, Elizabeth Zambrano Mendoza, Maria Fernanda Batistuzzo Vicentini Neffa, Karla Souza Campos, Leonardo Gomes da Fonseca, Renata Colombo Bonadio, Aley Talans, Oddone Freitas Melro Braghiroli, Maria Cecília Mathias-Machado, Jorge Sabbaga, Camila Motta Venchiarutti Moniz, Paulo Marcelo Gehm Hoff   +13 more
doaj   +1 more source

Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. [PDF]

, 2017
Predictive biomarkers have the potential to facilitate cancer precision medicine by guiding the optimal choice of therapies for patients. However, clinicians are faced with an enormous volume of often-contradictory evidence regarding the therapeutic ...
Beckman, Robert A., Boca, Simina M., Brody, Jonathan R., Madhavan, Subha, Marshall, John L., Pishvaian, Michael J., Rao, Shruti, Riazi, Shahla, Yabar, Cinthya S.   +8 more
core   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Treatment patterns and clinical outcomes in real‐world patients with small‐cell lung cancer in South Korea: A single‐center experience

International Journal of Cancer, EarlyView.
What's New? The emerging role of immunotherapy in small‐cell lung cancer treatment has not been fully elucidated, particularly outside of clinical trials. This single‐center retrospective cohort study examined real‐world treatment patterns and overall survival in South Korea during the 2018–2023 period.
Sehhoon Park, Danbee Kang, Jin Lee, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Hojoon Lee, Hyuna Lim, Xerxes Pundole, Juhee Cho, Myung‐Ju Ahn   +11 more
wiley   +1 more source

Rifaximin alleviates irinotecan-induced diarrhea in mice model

Annals of Medicine
Background Irinotecan is a chemotherapeutic drug widely used to treat solid tumors. However, its effectiveness is limited by the severely delayed onset of diarrhea.
Chengyi Huang, Huiyin Lan, Minghua Bai, Jinggang Chen, Shengkun Xu, Quanquan Sun, Qianping Chen, Wei Mao, Jin Jiang, Ji Zhu   +9 more
doaj   +1 more source

Globo‐H diagnostic stratification and identification of DUSP14 as a candidate target in colorectal cancer

International Journal of Cancer, EarlyView.
What's New? Colorectal cancer (CRC) is increasingly complicated by drug‐resistant tumors that limit the effectiveness of anticancer therapies. Because resistance mechanisms vary among patients and can evolve over time, personalized treatment strategies are needed.
Keren Zohar, Marco Strecker, Thomas Wartmann, Wenjie Shi, Frederike Stelter, Maximilian Doelling, Mihailo Andric, Or Kakhlon, Christian Täger, Denny Schanze, Michael Linnebacher, Michael Naumann, Daniel E. Stange, Dörthe Jechorek, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Computed Tomography Scans in the Prediction of Margin‐Negative Resection in Pancreatic Cancer Following Neoadjuvant Treatment: An Updated Systematic Review and Meta‐Analysis

iRADIOLOGY, EarlyView.
In this systematic review and meta‐analysis which evaluated the role of CT scan in the prediction of margin‐negative resection in pancreatic cancer following neoadjuvant treatment, the pooled sensitivity was 0.50 (95% CI: 0.34–0.66), and the pooled specificity was 0.75 (95% CI: 0.61–0.85).
Ehsan Emami, Dina Seyedi, Alireza Hassanpour, Faizan Bashir, Elina Attaran, Maryam Mostofi, Mohammadjavad Abbaspour, Farzin Tahmasbi Arashlow, Pariya Zibaei, Alaleh Alizadeh, Neda Tizro, Arash Saberian, Komeil Aghazadeh‐Habashi, Masoud Noroozi, Niloofar Deravi   +14 more
wiley   +1 more source